Navigation Links
BELLUS Health reports results for the fourth quarter of 2008
Date:2/26/2009

conditions, general conditions in the pharmaceutical and/or natural health products industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, changes to the competitive environment, and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. The results or events predicted in forward-looking information may differ materially from actual results or events. The Company believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. Unless otherwise stated, the forward-looking statements contained in this report are made as of the date of this report, and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable legislation or regulation. The forward-looking statements contained in this report are expressly qualified by this cautionary statement.

    BELLUS Health Inc.
    Consolidated Financial Information(1)
    (in thousands of US dollars, except per share data)

                              Three-month period ended        Year ended
                                     December 31             December 31
    -------------------------------------------------------------------------
    Consolidated Statements
     of Operations                 2008        2007        2008        2007
    -------------------------------------------------------------------------
    -------------------------------------------------------------------------

    Revenues:
      Gross sales                  $217         $ -        $423         $ -
      Discounts, returns and
       cooperative
       promotional incenti
'/>"/>
SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
10. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... A report out just last month ... option for avoiding cardiovascular disease is exercise and maintaining ... single most powerful predictor of death and survival, even ... family history of premature death -- a finding that ... fitness. , The Importance of Cardiovascular Screening , The ...
(Date:5/23/2015)... May 23, 2015 With the implementation ... are finding it increasingly difficult to provide their employees ... to provide adequate insurance for employees stand to face ... such an integral part of a business’s success or ... for businesses, Online USA Doctors has created a varying ...
(Date:5/23/2015)... May 23, 2015 A live auction will ... from hospitals, surgery centers and other medical facilities around the ... including endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... 27 and Thursday, May 28 starting at 9:00am CDT each ... 1400 N. 25th Avenue, Melrose Park, IL 60160. Anyone ...
(Date:5/22/2015)... Pasadena, Calif. (PRWEB) May 22, 2015 ... where technology, communication and capacity are intersecting to ... and across society, the opening speaker at WesternU's ... , California Lieut. Gov. Gavin Newsom, a former ... was the keynote speaker at the graduation ceremony ...
(Date:5/22/2015)... OH (PRWEB) May 22, 2015 River ... that Kyle Johnson, the health system’s Chief Financial Officer ... interests. Johnson has served as the company CFO since ... West will be joining the health system as CFO. ... an interim basis, while the Board of Trustees conducts ...
Breaking Medicine News(10 mins):Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2
... ... ... continuing to offer H1N1 nasal vaccines and H1N1 vaccine shots at four Centegra Primary Care (CPC) ... sites in Huntley, Woodstock, Crystal Lake and McHenry and will be open as follows: , ...
... , LA JOLLA, Calif., Dec. 3 ... Studies unanimously voted to elect three new members during its ... is co-founder and Managing Director of De Novo Ventures in Palo ... in early stage medical device and biotechnology companies. Dotzler founded Medicus ...
... , Research could lead to an ... known to result in cancer and genetic diseases , ... first time observed the movement of a single molecule of ... significantly, they have identified a previously unknown step that they ...
... primates , , THURSDAY, Dec. 3 (HealthDay News) -- A ... a primate study. , The drug, called SPC3649, uses a ... Unlike other antivirals that target the virus itself, the new ... that hepatitis C needs to replicate, the researchers explained. , ...
... , , CHICAGO, Dec. 3 ... medicine, called platelet-rich plasma therapy (PRP), is showing strong ... to a prominent dental researcher and editor of the ... James Rutkowski, DMD, PhD, reported at the recent annual ...
... Deutsches rzteblatt International contains the first scientific presentation ... virus (H1N1/09) in the German-speaking countries since the start ... the Dsseldorf University Hospital retrospectively evaluated data from a ... Dtsch Arztebl Int 2009; 106[47]: 770-6). Their medical-scientific ...
Cached Medicine News:Health News:Centegra H1N1 Vaccination Clinics Continue 2Health News:Centegra H1N1 Vaccination Clinics Continue 3Health News:Centegra H1N1 Vaccination Clinics Continue 4Health News:Salk Institute Board of Trustees Elects Leaders in Venture Capital and Publishing to its Membership 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 3Health News:New Hepatitis C Treatment Shows Promise 2Health News:New Hepatitis C Treatment Shows Promise 3Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2
(Date:5/22/2015)... Md. , May 22, 2015  RegeneRx Biopharmaceuticals, ... on tissue protection, repair and regeneration, today announced that ... is scheduled to present a corporate overview at two ... present at the SeeThruEquity 4 th Annual Microcap ... New York City at 11:00 am EDT. ...
(Date:5/22/2015)... May 22, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... peer-reviewed publication of the results of the Company,s ... preservative-free eye drops) for the treatment of dry ... (CAE ® ) model.  The exploratory study was ... were previously disseminated by the Company in a ...
(Date:5/22/2015)... , May 20, 2015 Research ... of the "Guide to Prepare Application Dossiers ... China (2014 Edition) " report to their ... is one of segment market of the most ... overseas medical device manufacturers and producers to penetrate ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... Inc., a privately held biopharmaceutical company that specializes ... ophthalmic pharmaceuticals, today reported that an independent Data ... of two pivotal Phase 3 clinical trials for ... diabetic macular edema (DME) under the current protocol, ...
... April 7 Glycotex, Inc. today announced the completion ... study evaluating the effect of investigational GLYC-101 gel on ... patients undergoing carbon dioxide laser skin resurfacing on the ... subjects completed the study. The comparison of each active ...
Cached Medicine Technology:Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout 2Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout 3Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis 2Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis 3
Curved shafts with serrated 1.5 mm upper and 2 mm lower jaws. Serrated cross action handle with slide lock and polished finish. Most popular size or model....
Folding forceps used for L161U. Manufactured in titanium....
Titanium. Thin jaws provide secure grasp of the folded lens for insertion into the eye. Reverse action forceps with angled shaft....
2.5 mm cups angled 50 degrees, 10 mm from angle to tip. Serrated handle with polished finish....
Medicine Products: